NCH-51 | CAS#848354-66-5 | HDAC inhibitor

NCH-51
featured

WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 406733

CAS#: 848354-66-5

Description: NCH-51, also known as PTACH, is a histone deacetylase (HDAC) inhibitor. NCH-51 tnhibits growth of various cancer cells in vitro (EC50 = 1.1 - 9.1 μM). NCH-51 could inhibit the cell growth of a variety of lymphoid malignant cells through apoptosis induction, more effectively than SAHA. NCH-51 upregulated anti-oxidant molecules including peroxiredoxin 1 and 2 and glutathione S-transferase at the protein level. NCH-51 exhibits cytotoxicity by sustaining ROS at the higher level greater than SAHA.

Chemical Structure

NCH-51

CAS# 848354-66-5

Product data Instruction

Theoretical Analysis

MedKoo Cat#: 406733
Name: NCH-51
CAS#: 848354-66-5
Chemical Formula: C20H26N2O2S2
Exact Mass: 390.14
Molecular Weight: 390.560
Elemental Analysis: C, 61.51; H, 6.71; N, 7.17; O, 8.19; S, 16.42

Price and Availability

Size	Price	Availability
500mg	USD 2650	2 months
1g	USD 3850	2 months
2g	USD 6450	2 months
Bulk inquiry Welcome, Customer: Please do not inquire quote if your intended use is for a patient since our products are for research use and for chemical synthesis use, not for human use . For in-stock products, we listed price in the web page. You may inquire prices for which sizes were not listed. If no price is listed, this means the product is not in stock at the moment, which may be available via custom synthesis. For cost-effective reason, minimum order of 1g is requested (typically very expensive). The lead time is usually 2-4 months. Quote of less than 1g will not be provided. MedKoo may not offer quote for below reasons: (1) current available synthetic method appears to be extremely expensive which is obviously not affordable to most customers; (2) Key raw material to make the product is temporally not available; (3) DEA controlled substances; (4) the product is under patent protection in customer’s country.

Synonym: NCH-51; NCH 51; NCH51. PTACH

IUPAC/Chemical Name: S-(7-oxo-7-((4-phenylthiazol-2-yl)amino)heptyl) 2-methylpropanethioate

InChi Key: MDYDGUOQFUQOGE-UHFFFAOYSA-N

InChi Code: InChI=1S/C20H26N2O2S2/c1-15(2)19(24)25-13-9-4-3-8-12-18(23)22-20-21-17(14-26-20)16-10-6-5-7-11-16/h5-7,10-11,14-15H,3-4,8-9,12-13H2,1-2H3,(H,21,22,23)

SMILES Code: CC(C)C(SCCCCCCC(NC1=NC(C2=CC=CC=C2)=CS1)=O)=O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Product Data:

Product Data

Instruction:

View handling instruction

Biological target:	PTACH (NCH-51) is a potent HDAC inhibitor with IC50s of 48 nM, 32 nM, and 41 nM for HDAC1, HDAC4, and HDAC6.
In vitro activity:	The novel histone deacetylase inhibitor NCH-51 induced expression of latent HIV-1 with minimal cytotoxicity. Using chromatin immunoprecipitation assays, this study observed a reduction of HDAC1 occupancy, histone hyperacetylation and the recruitment of positive transcription factors at the HIV-1 promoter in latently infected-cells under the treatment with NCH-51. Mutation studies of the long terminal repeat (LTR) revealed NCH-51 mediated gene expression through the Sp1 sites. When Sp1 expression was knocked-down by small interfering RNA, the NCH-51-mediated activation of a stably integrated HIV-1 LTR was attenuated. Reference: FEBS Lett. 2011 Apr 6;585(7):1103-11. https://pubmed.ncbi.nlm.nih.gov/21402072/
In vivo activity:	TBD

Solubility Data

	Solvent	Max Conc. mg/mL	Max Conc. mM
Solubility
	DMF	30.0	76.81
	DMSO	40.0	102.42
	DMSO:PBS (pH 7.2) (1:1)	0.5	1.28
	Ethanol	10.0	25.60

Preparing Stock Solutions

The following data is based on the product molecular weight 390.56 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:	1. Victoriano AF, Imai K, Togami H, Ueno T, Asamitsu K, Suzuki T, Miyata N, Ochiai K, Okamoto T. Novel histone deacetylase inhibitor NCH-51 activates latent HIV-1 gene expression. FEBS Lett. 2011 Apr 6;585(7):1103-11. doi: 10.1016/j.febslet.2011.03.017. Epub 2011 Mar 12. PMID: 21402072. 2. Sanda T, Okamoto T, Uchida Y, Nakagawa H, Iida S, Kayukawa S, Suzuki T, Oshizawa T, Suzuki T, Miyata N, Ueda R. Proteome analyses of the growth inhibitory effects of NCH-51, a novel histone deacetylase inhibitor, on lymphoid malignant cells. Leukemia. 2007 Nov;21(11):2344-53. doi: 10.1038/sj.leu.2404902. Epub 2007 Aug 9. PMID: 17690692.
In vitro protocol:	1. Victoriano AF, Imai K, Togami H, Ueno T, Asamitsu K, Suzuki T, Miyata N, Ochiai K, Okamoto T. Novel histone deacetylase inhibitor NCH-51 activates latent HIV-1 gene expression. FEBS Lett. 2011 Apr 6;585(7):1103-11. doi: 10.1016/j.febslet.2011.03.017. Epub 2011 Mar 12. PMID: 21402072. 2. Sanda T, Okamoto T, Uchida Y, Nakagawa H, Iida S, Kayukawa S, Suzuki T, Oshizawa T, Suzuki T, Miyata N, Ueda R. Proteome analyses of the growth inhibitory effects of NCH-51, a novel histone deacetylase inhibitor, on lymphoid malignant cells. Leukemia. 2007 Nov;21(11):2344-53. doi: 10.1038/sj.leu.2404902. Epub 2007 Aug 9. PMID: 17690692.
In vivo protocol:	TBD

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

Mass

Concentration

Volume

M. Wt* g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

Volume (to add to vial)

Mass (in vial)

Desired Reconstitution Concentration

Dilution Calculator

Calculate the dilution required to prepare a stock solution.

Concentration 1

Volume 1

Concentration 2

Volume 2

1: Nageshappa S, Carromeu C, Trujillo CA, Mesci P, Espuny-Camacho I, Pasciuto E,
Vanderhaeghen P, Verfaillie CM, Raitano S, Kumar A, Carvalho CM, Bagni C, Ramocki
MB, Araujo BH, Torres LB, Lupski JR, Van Esch H, Muotri AR. Altered neuronal
network and rescue in a human MECP2 duplication model. Mol Psychiatry. 2016
Feb;21(2):178-88. doi: 10.1038/mp.2015.128. Epub 2015 Sep 8. PubMed PMID:
26347316; PubMed Central PMCID: PMC4720528.

2: Victoriano AF, Imai K, Togami H, Ueno T, Asamitsu K, Suzuki T, Miyata N,
Ochiai K, Okamoto T. Novel histone deacetylase inhibitor NCH-51 activates latent
HIV-1 gene expression. FEBS Lett. 2011 Apr 6;585(7):1103-11. doi:
10.1016/j.febslet.2011.03.017. Epub 2011 Mar 12. PubMed PMID: 21402072.

3: Sanda T, Okamoto T, Uchida Y, Nakagawa H, Iida S, Kayukawa S, Suzuki T,
Oshizawa T, Suzuki T, Miyata N, Ueda R. Proteome analyses of the growth
inhibitory effects of NCH-51, a novel histone deacetylase inhibitor, on lymphoid
malignant cells. Leukemia. 2007 Nov;21(11):2344-53. Epub 2007 Aug 9. PubMed PMID:
17690692.

4: Suzuki T, Hisakawa S, Itoh Y, Maruyama S, Kurotaki M, Nakagawa H, Miyata N.
Identification of a potent and stable antiproliferative agent by the prodrug
formation of a thiolate histone deacetylase inhibitor. Bioorg Med Chem Lett. 2007
Mar 15;17(6):1558-61. Epub 2007 Jan 13. PubMed PMID: 17257837.

Your view history

NCH-51 featured